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The β-sheet plaques that are the most obvious pathological feature of Alzheimer's disease are composed of amyloid-β peptides and are highly
enriched in the metal ions Zn, Fe and Cu. The interaction of the full-length amyloid peptide, Aβ(1–42), with phospholipid lipid bilayers was
studied in the presence of the metal-chelating drug, Clioquinol (CQ). The effect of cholesterol and metal ions was also determined using solid-state
31P and 2H NMR. CQ modulated the effect of metal ions on the integrity of the bilayer and although CQ perturbed the phospholipid membrane,
the bilayer integrity was maintained. Model membranes enriched in cholesterol were studied under conditions of peptide association and
incorporation. Solid-state NMR showed that the bilayer integrity was preserved in cholesterol-enriched membranes in comparison to
phosphatidylcholine–phosphatidylserine bilayers. Changes in peptide structure, consistent with an increase in β-sheet, were observed using
specifically 13C-labelled Aβ(1–42) by magic angle spinning NMR. Results using aligned phosphatidylcholine bilayers and completely 15N-
labelled peptide indicated that the peptide aggregated. The results are consistent with oligomeric β-sheet structured peptides only partially
penetrating the bilayer and cholesterol reducing the membrane disruption.
© 2007 Elsevier B.V. All rights reserved.Keywords: Amyloid Aβ; Peptide–lipid interaction; Phospholipid membrane; Solid-state NMR; Structure; Cholesterol; Aligned lipid bilayer1. Introduction
The cause of neuronal dysfunction in Alzheimer's disease
(AD) has yet to be established. Interestingly, there is no
correlation between disease progression and the β-sheet plaques
that are the most obvious pathological feature of AD. Notably,
the plaques are highly enriched in the metals ions Zn, Fe and Cu
[1]. Disease progression correlates with soluble Aβ species and
evidence is accumulating that soluble oligomeric species of Aβ
are responsible for neuronal toxicity [2–4], possibly by
affecting membrane stability resulting in cell dysfunction [5].
Soluble oligomeric species of Aβ(1–42), and not the mono-
meric or fibrillar species of the peptide, were also found to
promote lipid release from cells [6], implicating membrane
disruption as a phenomenological cytotoxic mechanism for the⁎ Corresponding author.
E-mail address: fs@unimelb.edu.au (F. Separovic).
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doi:10.1016/j.bbamem.2007.08.027soluble oligomer. While cholesterol, phospholipids and mono-
sialogangliosides (GM1) were the main components released
soon after incubation with oligomeric Aβ, cell death occurred
only much later, further suggesting alteration in lipid compo-
sition or assembly as a possible mechanism of Aβ toxicity. The
formation of oligomeric aggregates was found to be promoted
by Aβ binding to membrane vesicles containing phospholipids
[7] and gangliosides [8].
The importance of lipid membranes in mediating Aβ toxicity
is further demonstrated by several studies with conflicting con-
clusions involving cholesterol, which orders membrane bilayers
[9,10]. An inverse correlation between Aβ toxicity and choles-
terol has been suggested [11], where Aβ toxicity was attenuated
in cholesterol-enriched cultured PC12 cells and enhanced in
cholesterol-depleted cells. In vivo studies, by contrast, suggested
cholesterol metabolism in the plasmamembrane is modulated by
Aβ [12,13] and cholesterol lowering (statin) drugs appear to
delay AD progression [14]. In vitro [15] and epidemiological
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cholesterol, which requires further study.
The interaction of soluble oligomers and cell membranes is
further complicated by the implication of metals in Aβ toxicity.
Cu2+-mediated toxicity has been proposed to be a result of a
metal ion binding site in the Aβ peptide involving the residues
His6, His13 and His14 [18–20]. The redox active metal ions
(Fe3+ and Cu2+) coordinated to Aβ [18,21–23] are capable of
Fenton-like redox reactions [20,24,25] and may be responsible
for the generation of reactive oxygen species. The resulting
oxidative stress [26] could alter normal neuronal membrane
content via lipid oxidation [27,28], including cholesterol [29],
and has been found to specifically induce Aβ cross-linking via
free radical reaction of the Tyr10 residue resulting in dimers
[18,20,25,30,31]. The formation of Aβ dimers may in turn seed
higher order oligomers species, although not necessarily along
the pathway leading to amyloid aggregates.
Intriguingly, the metal-promoted aggregation of Aβ is
reversed by treatment with metal chelators [32,33] such as the
quinoline drug Clioquinol (CQ) (Fig. 1). Clinically, CQ has
demonstrated encouraging results as a candidate for AD
treatment, as it is capable of crossing the blood–brain barrier
and inhibited or reversed the accumulation of Aβ deposits in
APP2576 transgenic mice [33]. A number of studies have hinted
at the action of CQ. Both CQ and Zn2+ blocked the toxicity of
Aβ(1–42) and Aβ(25–35)-induced Ca2+ influx into cultured
neuronal astrocytes and preserved the integrity of neuronal
membranes [34]. CQ also inhibited the toxicity of Aβ(1–40) and
attenuated the Cu2+-dependent toxicity in neuronal cultures of
Met(O)Aβ(1–42), an oxidised-Met35 derivative of Aβ(1–42)
[24]. H2O2 was produced by Met(O)Aβ(1–42) in the presence
of Cu2+, and this toxicity was ‘rescued’ by the addition of
catalase. A straightforward explanation attributes the apparent
effect of CQ to its metal coordinating properties, ultimately
inhibiting the generation of reactive oxygen species and related
downstream oxidation effects, as CQ was shown to inhibit co-
ordination of Cu2+ to Aβ [33] and the subsequent Cu-mediated
Aβ redox chemistry [35].
The interplay between CQ and the membrane composition
and integrity, correlated with Aβ structural changes, metal
interactions and oxidation chemistry, known to underpin
toxicity remains uncharacterized. Previously, when associated
with a phosphatidylcholine–phosphatidylserine membrane
system, Aβ(1–42) was found to bind to phospholipid head-
groups leading to a decrease in T2 relaxation time [36] and
appeared to form a peptide–lipid phase [18]. The toxic species
of the Aβ(1–42):Cu2+ complex when added to similar bilayer
systems did not perturb the lipid acyl chains as reported byFig. 1. Structure of 5-chloro-7-iodo-8-hydroxyquinoline, also known as
Clioquinol.fluorescence anisotropy measurements, thus implying that lipid
acyl chain perturbation is not involved in the toxic mechanism
of Aβ [18]. However, amyloidic species of the Aβ(1–42):Cu2+
complex did perturb the acyl chains, while not exhibiting any
neurotoxicity in cultured primary cortical neurons [18]. NMR
spectroscopy and fluorescence anisotropy measurements
showed that association of Aβ(1–42) to the phospholipid
bilayers and subsequent addition of Cu2+ and Zn2+ did not
cause significant perturbation of the bilayer [36]. Our previous
work showed preferential binding of Cu2+ to the peptide-
associated lipid phase, which suggested that the formation of
this new phase is representative of non-amyloidic Aβ(1–42):
Cu2+ species that exhibited neurotoxicity [18].
Given the positive clinical implications of CQ in relation to
Alzheimer's disease, we have extended these previous studies to
examine the effect of CQ on membrane integrity both alone and
together with Aβ(1–42) and Aβ(25–35) in phospholipid
bilayers with and without metal ions (Cu2+ and Zn2+). The
effect of cholesterol on membrane integrity was also investigat-
ed as an extension of our earlier studies on the comparison of
Aβ(1–42) to the shorter fragment Aβ(25–35) [37], which is
devoid of the metal binding sites. Human peripheral nerve
membranes [38] and rat synaptic plasma membranes of the
cerebral cortex, cerebellum and hippocampus [39] are rich in
cholesterol, ∼0.6 and 0.8 molar ratio, respectively, relative to
phospholipid. Cholesterol-enriched phospholipid bilayers have
a higher transition temperature and an accompanying increase in
order or decrease in membrane ‘fluidity’ of the acyl chain region
dependent on the cholesterol content [40], which may effect
peptide structure and insertion.
2. Materials and methods
2.1. Materials
Synthetic deuterated 1-palmitoyl(D31)-2-oleoyl-sn-glycero-3-phosphocho-
line (dPOPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), and
1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-L-serine] (POPS), supplied as dry
powders, and 1,2-di-O-hexyl-sn-glycero-3-phosphocholine (6-O-PC), and 1,2-
di-O-tetradecyl-sn-glycero-3-phosphocholine (14-O-PC), dissolved in chloro-
form, were purchased from Avanti Polar Lipids (Alabaster, USA) and used
without further purification. Cholesterol was purchased from Sigma Aldrich
(St. Louis, USA). 15N-enriched Aβ(1–42) peptide was purchased from W.M.
Keck Laboratory (Yale University, New Haven, USA). Specifically labelled
Aβ(1–42) peptide was made using standard FMOC-solid phase peptide
synthesis [33] purified by reverse phase HPLC and the product identified by
mass spectrometrywithm/z of 4519.11. The full-length peptide was labelledwith
sequence, DAEFRHDSGYEVHHQKLVFFAEDVGSNK[13C2]-G⁎[
13C1]-A⁎
IIG[13C1]-L⁎M VGGVV IA, and similarly, the shorter peptide Aβ(25–35),
GSNK[13C2]-G⁎[
13C1]-A⁎ IIG[
13C1]-L⁎M was synthesized as described [37].
13C2-Gly,
13C1-Ala and
13C1-Leu were purchased from Cambridge Isotope
Laboratories (Andover, USA), FMOC-succinamide (OSu) was purchased from
Auspep (Melbourne, Australia) and FMOC-protected amino acids were
synthesized and purified for use in peptide synthesis.
2.2. Preparation of multilamellar vesicles
dPOPC/POPS (1:1) or dPOPC/POPS/cholesterol (1:1:1) was dissolved in
chloroform and methanol (9:1) solution in a round bottom flask and the solvent
removed under vacuum resulting in a lipid film. Multilamellar vesicles (MLV)
were formed by suspending the lipid film in 0.5 ml of 50 mM Tris–HCl buffer
Table 1
2H quadrupolar splitting (ΔνQ) and
31P chemical shift anisotropy (CSA,Δσ) for
dPOPC/POPS MLV with Aβ(1–42), Aβ(25–35), CQ, Cu2+ and Zn2+ at 28 °C
and pH=7.2
Observed nuclei 2H 31P
(ΔνQ) kHz (Δσ) ppm
Sample CD2
(±0.3)
CD3
(±0.1)
CSA
(±2)
(a) dPOPC/POPS lipid (1:1) 25.1 2.4 −43
(b) Lipid+CQ (30:2) 24.5 2.1 −49
(c) Lipid+Aβ(1–42)
(associated) (30:1)
24.8 2.5 −43
(d) Lipid+Aβ(1–42)+CQ (30:1:2) 25.5 2.3 −48
(e) [21] Lipid+Aβ(1–42)+Cu2+ (30:1:1) 24.0 2.5 −32
(f) Lipid+Aβ(1–42)+CQ+Cu2+ (30:1:2:1) 25.3 2.4 −45
(g) [21] Lipid+Aβ(1–42)+Zn2+ (30:1:1) 25.0 2.5 −40
(h) Lipid+Aβ(1–42)+CQ+Zn2+ (30:1:2:1) 26.0 2.3 −45
(i) Lipid+Aβ(25–35) (associated) (30:1) 24.8 2.5 −47
(j) Lipid+Aβ(25–35)+CQ (30:1:2) 25.5 2.4 −44
(k) Lipid+Aβ(25–35)+CQ+Cu2+
(30:1:2:1)
25.4 2.4 −42
(l) Lipid+Aβ(25–35)+CQ+Zn2+
(30:1:2:1)
24.9 2.3 −44
ΔνQ was taken from the 90° edges of the powder pattern for the terminal CD3
and most ordered CD2.
31P CSAwas determined from discontinuities in overall
powder pattern.
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2.3. Association of peptides
Aβ(1–42) and Aβ(25–35) were dissolved in HFIP and dried into a thin film.
Pre-formed MLVs of either dPOPC/POPS (1:1) or dPOPC/POPS/cholesterol
(1:1:1), together with other components as appropriate, were added to the dry
peptide at a lipid/peptide ratio of 30:1, followed by several freeze–thaw cycles.
Each sample typically contained ∼1 mg of Aβ(1–42) or ∼0.25 mg of Aβ(25–
35) and ∼5 mg lipid.
2.4. Addition of CQ
As CQ is insoluble in water and many convenient organic solvents at the
required stock solution concentrations, it was dissolved at 30 mg/ml in 10 mM
NaOH for dilution into MLV suspensions at a total lipid/CQ mol ratio 30:2. pH
was adjusted back to 7.2 with 10 mM HCl following addition.
2.5. Addition of metal ions
Copper and zinc ion stock solutions were prepared using 0.1 M copper
glycine (CuGly2) solution or 0.1 M zinc glycine solution (ZnGly2), respectively,
by dissolving 1:2 mole ratio of metal chloride with glycine in de-ionised water.
Copper and zinc glycine solution was added to the phospholipid bilayer samples
at lipid/metal mol ratio of 30:1.
The order of addition of peptide, CQ, and metal to MLV was dictated by the
need to protect against the disruption of MLV structure by Cu2+, as reported
previously [36]. For data presented here, peptide was added first to MLV,
followed by CQ, then metals. Other possible permutations of order-of-addition
to MLV (e.g., CQ, peptide, then metal) were also performed, but had little effect
(data not shown). This invariance to the order in which components were added
suggests that the observations represent an equilibrium state.
2.6. Incorporation of Aβ(1–42)
Aβ(1–42) was dissolved in hexafluoroisopropanol (HFIP) (Sigma Aldrich,
St. Louis, USA) and added to MLV suspension resulting in approximately 10%
v/v HFIP. The mixture was freeze-dried overnight and the film re-suspended
with distilled water and freeze–thawed for several cycles. The total lipid to
peptide to mole ratio was 30:1.
2.7. Aβ(1–42) in aligned membrane bilayers
Solid-state NMR samples of membrane proteins in magnetically aligned
phospholipid bicelles are prepared by dissolving purified, 15N-labelled proteins in
a 6-O-PC aqueous solution, and then adding this solution to a dispersion of 14-O-
PC in water [41]. Five samples were made each using 1 mg of dry, uniformly 15N-
labelled Aβ(1–42), which was first dissolved in trifluoroethanol (TFE) or a
mixture of TFE/chloroform and sonicated for 5–30 min in a bath sonicator. The
peptide solution was filtered using a 0.2-μmTeflon filter (PTFEMillex,Millipore)
to eliminate any undissolved particles. Solvent was evaporated under a stream of
N2 gas to obtain a thin, transparent peptide film, which was placed under high
vacuum overnight. The ether lipids were similarly prepared by drying with N2 gas
and placing under high vacuum overnight. Bicelles with ratio of 14-O-PC/6-O-PC
(q)=3.2 and 28%w/v with peptide included were prepared by adding 9.5 mg 6-O-
PC in 100 μl aqueous solution to the dry peptide film. A dispersion of 14-O-PC in
water (46.5 mg in 75 μl) was prepared by vortexing extensively, freeze–thawing
three times (liquid nitrogen and warming to 40 °C). The peptide/6-O-PC solution
was then added to the 14-O-PC dispersion, warmed to 40 °C, and an additional
25 μl of water used to complete the transfer. The resulting solution was briefly
vortexed, freeze–thawed approximately five times and then allowed to equilibrate
to room temperature. Upon bicelle formation, the previously white dispersion of
14-O-PC becomes a clear solution between 0 and 10 °C. Since the peptide-bicelle
sample was extremely viscous at room temperature, the bicelle solution was pre-
chilled in an ice-water bath for a few seconds before transferring to an NMR tubeusing a chilled glass Pasteur pipette. A small, flat-bottomed NMR tube with 5-mm
outer diameter was filled with ∼170 μl of the bicelle solution and sealed with a
tight-fitting rubber septum, pierced with a thin syringe to remove excess air from
the sample and to create a tight seal.
2.8. Solid-state NMR (SS-NMR)
2H and 31P NMR static and 31P and 13C magic angle spinning (MAS)
experiments were conducted on a Varian Inova 300-MHz spectrometer (Palo
Alto, CA, USA) operating at a resonance frequency of 300 MHz for 1H. Static
spectra were acquired at 28 °C, using a Doty (Columbia, SC, USA) 5-mm
double or triple resonance probe.
2H static solid or quadrupolar echo experiments [42] on samples without
cholesterol were conducted using the double resonance probe with a π/2 pulse of
6 μs and a spectral width of 250 kHz, with a recycle delay of 0.5 s and line
broadening of 100 Hz. The preacquisition delay for wideline 2H detection for
samples with cholesterol was optimised, such that Fourier transform was
performed for a FID beginning at the top of the echo, by first constructing an
effectual 10-MHz spectral width spectrum. This was accomplished by
shortening the second delay of the echo, collecting an array of 500-kHz spectral
width (2.0-μs dwell time, the maximum digitisation rate of the receiver) spectra
with the preacquisition delay incremented by 0.1 μs, interleaving points from the
resulting array of FIDs, left shifting the interleaved FID to the centre/top of the
echo, and inspecting the appropriately down-sampled Fourier transform with
zero linear phase correction. The required number of left-shifted points was then
translated to a preacquisition delay such that a left shift of FID points for a 500-
kHz wide spectrum corresponds to the centre/top of the echo in routine 1D 2H
spectra. These routine spectra were collected with audio filter bandwidth set to
70 kHz, and down-sampled by a factor of 4 to a spectral width of 125 kHz. This
approach accomplishes a similar optimisation to that performed numerically
when spline fitting the FID to interpolate between digitised points [43].
For static 31P experiments using the double resonance probe with proton
decoupling, a π/2 pulse of 4 μs and a spectral width of 62 500 Hz were used,
with a recycle delay of 1.5 s and line broadening of 100 Hz. For static 31P
experiments using the triple resonance probe, a π/2 pulse of 5 μs was applied
with a recycle delay of 2 s with similar line broadening. Static experiments for
samples with cholesterol used a short Hahn-echo pulse sequence with optimised
preacquisition delays and a spectral width of 125 kHz, down-sampled by a factor
Fig. 2. 2H (left) and 31P NMR (right) static spectra of dPOPC/POPS (1:1 mol/mol) hydrated dispersions at pH 7: (a, b) with Aβ(1–42); (c, d) with CQ showing an
isotropic peak forming; (e, f) with Aβ(1–42) and CQ added; (g, h) with Aβ(1–42), CQ and Cu2+ ions; and (i, j) with Aβ(1–42), CQ and Zn2+ ions.
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phosphoric acid (H3PO4) as 0 ppm for
31P experiments. T2 experiments for
31P
were carried out with 6-kHz MAS using a Hahn-echo sequence with π/2 pulse
of 5 μs and variable rotor-synchronized echo delay. T2 non-linear data were
fitted using Gnuplot 4.0 [44].
13C cross polarisation (CP)-MAS experiments [45,46] were carried out at
6 kHz using the 5-mm triple resonance probe and a CP pulse sequence with π/
2=4.5 μs for proton nuclei, 1-ms contact time, 2-s recycle delay, spectral width
of 30 kHz, typically 30,000 scans and line broadening of 50 Hz. The 13C
chemical shifts were referenced externally to tetramethylsilane (TMS) as 0 ppm
and adamantane at 38.48 and 29.46 ppm [47].
15N NMR experiments were conducted on a Bruker (Karlsruhe, Germany)
Avance 750-MHz spectrometer using a home-made 5-mm double resonance
(PISEMA) [48,49] probe. 15N CP spectra were acquired at 40 °C using a contact
time of 1 ms, 1H pulse length of π/2=5 μs with 50-kHz SPINAL64 decoupling,
recycle delay of 6 s, spectral width of 50 kHz and 500-Hz line broadening.Table 2
2H quadrupolar splitting (ΔνQ),
31P chemical shift anisotropy (CSA, Δσ) and
31P MAS T2 relaxation time for dPOPC/POPS/cholesterol MLV with and
without Aβ(1–42) 30:1 lipid/peptide ratio at 28 °C, pH=7.23. Results
3.1. The effect of CQ on membrane integrity in the presence of
Aβ(1–42) and Aβ(25–35)
CQ, when added alone to dPOPC/POPS phospholipid mem-
brane bilayers, decreased the quadrupolar splitting of the most-Fig. 3. Schematic showing the difference between ‘associated’ and ‘incorpo-
rated’ peptides with lipid bilayers.ordered CD2 and terminal CD3 dPOPC sn-1 acyl chain segments
by∼10% (Table 1(a) vs. (b)). CQ also caused∼15% increase in
the axially symmetric chemical shift anisotropy (CSA) of the
phospholipid headgroup relative to MLV bilayers alone, and
induced a small fraction of the sample to form an isotropic peak
as seen in both the 31P and the 2H spectra (Figs. 2(c, d)). The
observation of an isotropic peak suggests that CQ perturbs the
integrity of the lipid bilayer [50–52].
Full-length Aβ(1–42) and the hydrophobic segment Aβ(25–
35) peptides, when individually associated with dPOPC/POPS
phospholipid membrane bilayers, had similar or less impact than
CQ added alone. Each peptide caused a ∼10% reduction in
quadrupolar splitting at both the terminal CD3 and the most
ordered CD2 segments of the dPOPC sn-1 acyl chains (Table 1
(c) and (i) vs. (a)). The full-length peptide and hydrophobic
subpeptide differ in their effect, however, on the phospholipid
headgroups. Aβ(1–42) had no apparent effect, while Aβ(25–
35) caused a ∼10% increase in the axially symmetric 31P CSA.Observed nuclei 2H 31P 31P
(ΔνQ) kHz (Δσ) ppm Isotropic
Sample CD2
(±0.5)
CD3
(±0.1)
CSA
(±2)
T2
(ms)
(a) dPOPC/POPS/Cholesterol
lipid (1:1:1)
45.4 3.8 −40 10.6±0.6
(b) Lipid+Aβ(1–42)
(associated)
45.8 4.3 −38 5.2±0.3
(c) Lipid+Aβ(1–42)
(incorporated)
46.7 4.1 −38 4.2±0.2
ΔνQ was taken from the 90° edges of the powder pattern for the terminal CD3
and most ordered CD2.
31P CSAwas determined from discontinuities in overall
powder pattern.
Fig. 4. 2H NMR (left) and 31P NMR (right) spectra of: (a, b) dPOPC/POPS/cholesterol (1:1:1 mol/mol) hydrated dispersions at pH 7.2; (c, d) dPOPC/POPS/cholesterol
with associated Aβ(1–42); and (e, f) dPOPC/POPS/cholesterol with incorporated Aβ(1–42).
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Addition of CQ to POPC/POPS membranes following Aβ(1–
42) peptide increased the 31P CSA (Table 1(d)) similar to CQ
alone (Table 1(b)), and in contrast to the lack of effect of Aβ(1–
42) alone (Table 1(c)). Further addition of Cu2+ or Zn2+ ions
caused a reduction of the 31P CSA similar to that of Aβ(1–42)
alone associated with the phospholipid membrane (Table 1(f,
h)). Addition of CQ following Aβ(25–35), on the other hand
reduces the CSA (Table 1(j)) to that of the lipid membrane
control (Table 1(a)), in contrast to the increased CSA of both the
CQ and Aβ(25–35) alone (Table 1(b, i)). The further addition of
Cu2+ or Zn2+ ions had little effect on both the 31P CSA and the
2H splittings (Table 1(k, l)).
3.2. The effect of Aβ(1–42) on
phospholipid-cholesterol membranes
Our earlier results with Aβ(1–42) and phospholipid vesicles
[36] showed that a difference in bilayer stability is that the
peptide was ‘associated’, i.e., added after vesicle formation, or
‘incorporated’, i.e., solubilized with the lipid prior to vesicle
formation (Fig. 3). Aβ(1–42), whether associated with or
incorporated in cholesterol-enriched dPOPC/POPS MLV
bilayers, produced a slight increase in 2H quadrupolar splittingFig. 5. 13C CP-MAS NMR spectra of: (a) HFIP-dissolved and dried Aβ(1–42),
(b) dPOPC/POPS/cholesterol, (c) dPOPC/POPS/cholesterol with associated
Aβ(1–42), and (d) dPOPC/POPS/cholesterol with incorporated Aβ(1–42).
Carbonyl chemical shifts for HFIP-treated Aβ(1–42) are ∼177.5, versus
∼173.6 and ∼172.8 ppm when either associated or incorporated with dPOPC/
POPS/cholesterol MLV bilayers.at both ends of the acyl chain and a more significant decrease in
31P CSA (Table 2). In addition to overall narrowing the apparent
31P CSA, the characteristic features of the axially symmetric
CSA apparent in the MLV sample without peptide become
broader (Fig. 4). The static 2H and 31P measurements did not
discriminate significantly, however, between the ‘associated’
and ‘incorporated’ methods of addition to MLV bilayers. Mea-
sured MAS 31P T2 relaxation times, however, decreased sig-
nificantly in the presence of Aβ(1–42) from 10.6 ms in the
MLV without peptide to 5.2 ms for ‘associated’ and 4.2 ms for
‘incorporated’ peptide (Table 2).
CP-MAS NMR studies of 13C-enriched specific sites in the
C-terminal region of the full-length peptide also indicated
differences in peptide structure irrespective of ‘incorporating’ or
‘associating’ the peptide. After solubilizing the Aβ(1–42)
peptide in HFIP and drying it, but before exposure to dPOPC/
POPS/cholesterol MLV bilayers, the Ala30 and Leu34 residues
have an isotropic chemical shift of∼177.5 ppm. Upon exposure
to dPOPC/POPS/cholesterol bilayers, the carbonyl resonances
move upfield by approximately 4 ppm (Fig. 5).
In order to probe the tertiary fold of the peptide, SS-NMR
NMR experiments were performed using fully 15N-labelled
Aβ(1–42) with phospholipid bicelles aligned in the magnetic
field. Although the 15N spectra of Aβ(1–42) in aligned bicelles
initially appeared to show peptide alignment, but for each vari-
ation in sample preparation, the peptide appeared to aggregateFig. 6. 15N CP NMR spectrum of uniformly labelled 15N-Aβ(1–42) in aligned
bicelles of 14-O-PC/6-O-PC (P/L ∼1:300) at 40 °C after 4096 scans.
Fig. 7. 31P NMR spectrum of aligned bicelles of 14-O-PC/6-O-PC with
uniformly labelled 15N-Aβ(1–42) in (P/L ∼1:300) at 40 °C, with the two 31P
resonances peaks due to the short and long chain phospholipids [41].
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evident (Fig. 6). The 31P NMR spectra at 40 °C (Fig. 7) showed
that the phospholipids were aligned whereas the 15N spectra
indicated that the peptide was not.
4. Discussion
Our earlier studies of dPOPC/POPS MLV with associated
Aβ(1–42) showed a small disordering effect on the lipid acyl
chains of the sn-1-palmitoyl chain as indicated by only slightly
reduced maximum CD2 and CD3 quadrupolar splittings [36].
Although a number of models could be used to explain this
reduction in order parameter, including a change in wobble or
tilt angle of the lipids, a similar reduction in order parameter has
been attributed to an 1 Å thinning of the membrane [53]. There
was little effect of the peptide on the phosphate headgroups as
indicated by the similar axially symmetric “powder” patterns. In
the presence of Cu2+ ions, however, there was a dramatic
reduction in 31P CSA of the peptide-associated MLV, and an
additional slight disordering effect in the upper region of the
acyl chains [36] (Table 1(e)). Aβ(1–42) with Zn2+ had a similar
but less dramatic effect on headgroups, and almost no change in
the order of the palmitoyl chain. Notably, in the absence of
Aβ(1–42) peptide, Cu2+ destabilizes the MLV structures,
causing much of the phospholipid to form relatively small,
isotropically tumbling structures [36].
Clearly, metals and Aβ(1–42) mutually modulate their
interaction with dPOPC/POPS phospholipid membranes. If the
mode of action of CQ is solely the chelation of metals, then the
data for Aβ(1–42) associated alone with MLV should resemble
that when CQ is included together with both Aβ(1–42) and
metal ions, and CQ itself should not perturb membrane struc-
ture. Surprisingly, however, CQ added alone to MLV had the
effect of disordering the terminal sn-1 CD3 of dPOPC, while
increasing the 31P CSA (from −43 to −49 ppm). For typical
phospholipid 31P chemical shift tensors undergoing fast axial
rotation about the long axis of the lipid and other modes of
disorder [54–59], this increase in CSA upon addition of CQ
may correspond to headgroup orientations extending more
upright from the plane of the lipid bilayer, as previously reported
for another heterocyclic pharmaceutical [60], and a possibleconsequence of CQ occupancy in the more polar headgroup area
rather than further down into the interfacial/lipid carbonyl area.
CQ, when added to the bilayer alone also caused the appearance
of an isotropic peak, indicating a loss in integrity of the bilayer
(Figs. 2(c, d)). However, the overall 2H quadrupolar splitting
was not reduced with the formation of the isotropic peak,
suggesting the persistency of large bilayer structures. The
isotropic peak was small in the 31P spectra, which suggested the
extent of CQ perturbation to be sufficient only for averaging the
CD3 splittings but insufficient for averaging the
31P CSA [36].
The amyloidogenic human Islet Amyloid Polypeptide, which
forms small aggregates that kill cells by disrupting the cellular
membrane, also produces an isotropic 31P chemical shift signal
indicative of membrane fragmentation [61].
In the presence of Aβ(1–42), but still without metals, the
terminal sn-1 CD3 regained the order typical of unperturbed
MLV with the addition of CQ, but the headgroups 31P
anisotropy remained almost as broad (−48 ppm) as with CQ
alone. The headgroup appeared to be more restricted when CQ
was added after Aβ(1–42) to the membrane bilayers as seen by
the increase in 31P CSA, while an opposite effect was seen for
Aβ(25–35) possibly due to Aβ(25–35) penetrating the bilayer
[62]. Taken together, this effect on model membranes without
metal ions suggests that CQ may potentially have an additional
mode of action in modulating cytotoxic activity of Aβ(1–42).
The effect of CQ on membranes with Aβ(1–42) and
Aβ(25–35) peptides was examined in the presence of Cu2+ and
Zn2+. Subsequent addition of Cu2+ ions after CQ and Aβ(1–42)
gave lipid 31P CSA and 2H quadrupolar splittings similar to the
results seen when Aβ(1–42) was associated with the phospho-
lipid bilayers alone, as if CQ has reduced the effect of metal ions.
In contrast to Aβ(1–42), the C-terminal mostly hydrophobic
subpeptide Aβ(25–35) increased the 31P CSA on its own, but
prevented the increase in CSA by CQ, whether metal was pres-
ent or not. If CQ counteracts Aβ(1–42) toxicity by abolishing
the formation of Cu2+ coordination required for peptide toxicity
[21], then the toxicity of Aβ(25–35) which excludes histidine–
metal binding, would not be ‘rescued’ by CQ. The differences
in lipid changes in the presence of Aβ(1–42) compared to
Aβ(25–35) further substantiate the latter having a different
toxicity mechanism to Aβ(1–42).
CQ bears some structural similarity to tryptophan and
cholesterol, which are both known for their tendency to locate at
the interfacial region of the phospholipid bilayers [9,10,63], and
as cholesterol occurs naturally in cell membranes with some
correlations to Aβ cytotoxicity [11–13], we examined the
interaction between Aβ(1–42) and cholesterol-containing MLV.
Although CQ and cholesterol are both aromatic compounds
with a relationship to the progression of AD [33], their effects
on lipid bilayers in the presence of Aβ(1–42) are rather dif-
ferent. Cholesterol increases segmental order at both the top and
bottom of the sn-1 chain [10,40,42] and causes a reduced 31P
CSA [37,40], opposite to the effect seen with CQ. Our earlier
studies of cholesterol-enriched membranes in the presence of
the fibril forming Aβ(25–35) showed a further increase in the
2H splittings [37]. Both associated and incorporated Aβ(1–42)
also caused a further ordering of the sn-1 acyl chain, and even
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bilayers. T2 relaxation measurements, in contrast, did not ob-
viously follow suit: T2 for dPOPC/POPS MLV increased from
6.2 ms [37] to 10.6 ms with cholesterol, but decreased again
to 5.2 and 4.2 ms upon association and incorporation of
Aβ(1–42), respectively. Conversely to the effect observed
upon addition of CQ to MLV, the decrease in phospholipid 31P
CSAwhen cholesterol was included may correspond to a more
lateral orientation of the headgroup as lipids are spaced further
apart from one another [64,65], an effect made more so by the
presence of Aβ(1–42). The increase in T2 relaxation time with
cholesterol indicates a decrease in intensity of slow modes of
bilayer disorder [57,59]. The decrease in T2 upon addition of
Aβ(1–42), as well as the corresponding broadening of 31P
static lineshape features in Figs. 3(d) and (f) relative to (b),
similar to spectral effects noted in aligned lipid–peptide sys-
tems, [66] indicates that slow-motion headgroup disorder is
reintroduced, in spite of the presence of cholesterol. The lack
of significant impact on acyl chain order suggests that at least
a part of the Aβ(1–42) occupies the interfacial regions of the
MLV bilayers. Both the full-length peptide and the fragment
are toxic to cells and the opposite effects observed for the
31P CSA for Aβ(25–35) in comparison to Aβ(1–42) indicate
that their membrane interactions are rather different.
The 13C-detected CP-MAS spectra (Fig. 5) provide evidence
for the structural conformation of Aβ(1–42). Organic solvents
such as TFE [63] or HFIP used here to initially solubilize
Aβ(1–42) prior to introducing MLV lipid bilayers induced
α-helical structure, as noted by circular dichroism (data not
shown) and correlation of the ∼177.5 ppm isotropic chemical
shift of the 13C=O (Fig. 5) to secondary structures observed by
solid-state NMR [67,68]. Notably, upon association or incorpo-
ration of HFIP-treated Aβ(1–42) with dPOPC/POPS/cholester-
ol MLV, the carbonyl resonances of Ala30 and Leu34 moved
upfield to isotropic chemical shifts characteristic of extended β-
strand conformations [67], similar to previous experience with
Aβ(25–35) interacting with dPOPC/POPS MLV lipid bilayers
[37]. The two chemical shifts may correspond to Ala
(173.6 ppm) and Leu (172.8 ppm), which were not resolved in
the dried peptide because the linewidths were broader than in the
membrane-associated samples. Alternatively, the two peaks
could be due to: (i) Aβ(1–42) inserted deeper into the bilayer,
and (ii) Aβ(1–42) unable to penetrate the bilayer due to the
higher membrane order due to cholesterol. Peptide aggregation
may have occurred, possibly due to peptides being unable to
fold/unfold in the bilayer or peptide aggregating in the bilayer
and being expelled, as reported for Aβ40 with saturated PC
bilayers [69]. Interestingly, cholesterol also inhibited the
insertion of the peptide fragment Aβ(25–35) in phospholipid
bilayers [70].
Significantly, when attempting incorporation of Aβ(1–42)
with the zwitterionic PC ether lipids, the peptide may have
aggregated in the bicelles with a broad distribution of orien-
tations but, since the lipid was well aligned (Fig. 7), the aggre-
gates are more likely to be in the aqueous phase as similarly
observed in PC vesicles [69]. On the other hand, the interactions
between lipid and peptide persist through the experimental timerequired to collect the 2H and 31P static and 31P and 13C MAS
spectra in our anionic membrane systems, even at ten times
greater concentration than in the bicelle samples, as detailed
above. While there are several clear differences between the
ether–PC bicelle and MLV bilayer lipids, the apparent surface
interactions of the peptide suggest that the variation in phos-
pholipid headgroup composition between the two systems
provides the principal difference.
Our previous studies have shown that Aβ(1–42) interactions
with phospholipid bilayers result in an oligomeric β-sheet
structure as a toxic species [18], and result in no significant
membrane perturbation [36]. In the present study, Aβ(1–42)
when ‘associated’ with cholesterol-enriched bilayers was found
to perturb the phospholipid acyl chain region and retain a β-
sheet structure. Aβ42 appeared to aggregate with aligned PC
bicelles, even at one tenth of the concentration in PC/PS bilayers,
and may explain the lack of significant membrane disruption
observed by NMR. A possible mode of Aβ(1–42) cell toxicity
that does not involve considerable membrane perturbation may
depend on peptide electrostatic interactions with the membrane
bilayer, e.g., with charged phospholipids such as PS, which is
associated with apoptosis [71]. The histidine residues in
particular may play a major role in membrane binding since
N-methylation of the His residues has been shown to inhibit
Aβ–membrane interactions [21].
Cholesterol appeared to preserve the bilayer stability when
‘incorporated’ Aβ(1–42) was included. Earlier results for
Aβ(1–42) incorporated into PC/PS bilayers [36] show a loss
of bilayer stability, which is consistent with cholesterol playing a
protective role in Aβ toxicity. Comparison of ‘associated’
Aβ(1–42) with phospholipid bilayers [18] and cholesterol-
enriched bilayers suggests that association of Aβ(1–42) alone
does not significantly perturb the membrane integrity. However,
with the addition of cholesterol, an increase in 2H quadrupolar
splitting and a decrease in 31P CSA were seen, together with a
decrease in T2. The peptide seemed to maintain an interaction
with the phospholipid headgroup but, since cholesterol de-
creases membrane fluidity and sits in the acyl chain region, the
lipid headgroups are further apart with the addition of choles-
terol, which may affect the peptide interaction with the mem-
brane. The 13C NMR data suggest that incorporated and
associated Aβ(1–42) appeared to have differences in secondary
structure, and differences in membrane association have
previously been reported for Aβ(1–40) [72]. Our 15N results
showing unoriented peptide in aligned bicelles supports
previously reported results for Aβ(1–42) in PC/PS [18] and
Aβ40 with PC vesicles [69] that aggregation may be taking
place on the membrane surface and preventing transmembrane
insertion. The ‘associated’ Aβ(1–42) would then have little
effect on the order of the 2H acyl chains and decrease that of the
31P headgroups. Possibly the associated species has a greater
effect on the cholesterol containing phospholipid bilayers, which
represent a more biologically relevant model system, by al-
lowing a greater lipid–peptide interaction as reflected by the
resulting decrease in 31P T2.
Incorporated Aβ(1–42) appeared to enhance the effect of
cholesterol by further ordering the lipid acyl chain while
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headgroup relaxation time from 10.6 ms to∼5 ms (Table 2) also
indicated an increase in low-frequency motions, consistent with
‘immobilisation’ of the lipid in the presence of the peptide [73].
Broadening of the characteristic 31P axially symmetric features
for cholesterol-enriched PC/PS MLV upon addition of peptide
was greater than that which would be consistent with the de-
creased T2 relaxation times as measured by
31P MAS. This may
result from the interaction of the phospholipids with aggregated
species of Aβ peptides, which is modulated by the fluidity of the
bilayer [70,74]. The results suggest that Aβ(1–42) inserted into
the cholesterol enriched bilayer as reflected by the increase in 2H
quadrupolar splitting of the chains and the simultaneous de-
crease in the 31P CSA of the headgroup, as a result of an increase
in lipid headgroup area caused by peptide insertion. Incorporated
had a similar or greater effect than associated peptide, which can
be explained by each having the same fundamental interaction,
but that the incorporated method is simply more thorough in
establishing the interaction. The similar 13C shifts also is con-
sistent with the peptide having similar structure and lipid
interaction. Also, since cholesterol decreases the fluidity and
enhances the stability of membranes, the effect is less dramatic
than that seen for phospholipid bilayers without cholesterol [36],
where the membrane integrity was disrupted by Aβ(1–42)
incorporation. A possible explanation, which accounts for the
solid-state NMR data presented here and an interfacial location
of Aβ(1–42), is that bilayer order influences the depth of
insertion of the peptide, as reported for the antimicrobial peptide
LL-37 [75]. Although Aβ peptides and metals interact with
model membranes, their effects are modulated by the compo-
sition of the lipid bilayer and the presence of metal-chelating
drugs, which together can maintain bilayer stability.
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